Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
0.7936
+0.0386 (5.11%)
At close: Sep 17, 2025, 4:00 PM EDT
0.7936
0.00 (0.00%)
After-hours: Sep 17, 2025, 5:11 PM EDT
Akari Therapeutics, Employees
As of December 31, 2024, Akari Therapeutics, had 9 total employees, including 8 full-time and 1 part-time employees. The number of employees decreased by 3 or -25.00% compared to the previous year.
Employees
9
Change (1Y)
-3
Growth (1Y)
-25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,363,000
Market Cap
25.88M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9 | -3 | -25.00% |
| Dec 31, 2023 | 12 | -3 | -20.00% |
| Dec 31, 2022 | 15 | 6 | 66.67% |
| Dec 31, 2021 | 9 | 0 | - |
| Dec 31, 2020 | 9 | -1 | -10.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AKTX News
- 8 hours ago - Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer - GlobeNewsWire
- 7 days ago - Akari Therapeutics, Plc (AKTX) Discusses At Virtual Investor Closing Bell Series Call (Transcript) - Seeking Alpha
- 12 days ago - Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 14 days ago - Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series - GlobeNewsWire
- 4 weeks ago - Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech - GlobeNewsWire
- 7 weeks ago - Akari Therapeutics Releases Virtual Investor “What This Means” Segment - GlobeNewsWire
- 2 months ago - Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers - GlobeNewsWire
- 2 months ago - Akari Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference - GlobeNewsWire